ALKERMES Company Profile
✉ Email this page to a colleague
What is the competitive landscape for ALKERMES, and when can generic versions of ALKERMES drugs launch?
ALKERMES has six approved drugs.
There are thirty US patents protecting ALKERMES drugs.
There are two hundred and thirty-six patent family members on ALKERMES drugs in thirty-five countries and thirteen supplementary protection certificates in eight countries.
Summary for ALKERMES
International Patents: | 236 |
US Patents: | 30 |
Tradenames: | 6 |
Ingredients: | 5 |
NDAs: | 6 |
Patent Litigation for ALKERMES: | See patent lawsuits for ALKERMES |
PTAB Cases with ALKERMES as petitioner: | See PTAB cases with ALKERMES as petitioner |
PTAB Cases with ALKERMES as patent owner: | See PTAB cases with ALKERMES as patent owner |
Drugs and US Patents for ALKERMES
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Alkermes Inc | LYBALVI | olanzapine; samidorphan l-malate | TABLET;ORAL | 213378-004 | May 28, 2021 | RX | Yes | No | 9,517,235 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Alkermes Inc | ARISTADA | aripiprazole lauroxil | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 207533-003 | Oct 5, 2015 | RX | Yes | Yes | 10,112,903 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Alkermes Inc | ARISTADA | aripiprazole lauroxil | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 207533-001 | Oct 5, 2015 | RX | Yes | No | 9,452,131 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ALKERMES
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Alkermes | VIVITROL | naltrexone | FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 021897-001 | Apr 13, 2006 | 6,534,092 | ⤷ Try a Trial |
Alkermes | VIVITROL | naltrexone | FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 021897-001 | Apr 13, 2006 | 6,264,987 | ⤷ Try a Trial |
Alkermes | VIVITROL | naltrexone | FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 021897-001 | Apr 13, 2006 | 6,596,316 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for ALKERMES Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Israel | 296695 | ⤷ Try a Trial |
Australia | 2020250309 | ⤷ Try a Trial |
World Intellectual Property Organization (WIPO) | 2005107753 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for ALKERMES Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2316456 | 17C1058 | France | ⤷ Try a Trial | PRODUCT NAME: NALTREXONE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE,EN PARTICULIER CHLORHYDRATE DE NALTREXONE ET,BUPROPION OU SEL PHARMACEUTIQUEMENT ACCEPTABLE,EN PARTICULIER CHLORHYDRATE DE BUPROPION; REGISTRATION NO/DATE: EU/1/14/988 20150330 |
1675573 | 92427 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: ARIPIPRAZOLE |
0454436 | 97C0012 | Belgium | ⤷ Try a Trial | PRODUCT NAME: OLANZAPINE; REGISTRATION NO/DATE: EU/1/96/022/001 19960927 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.